HiberCell
  • About
    • Mission
    • Team
    • Careers
  • Our Science
  • Programs
    • Pipeline
    • Odetiglucan
    • HC-5404
    • HC-7366
  • Patients & Caregivers
  • News & Publications
  • Contact
  • About
    • Mission
    • Team
    • Careers
  • Our Science
  • Programs
    • Pipeline
    • Odetiglucan
    • HC-5404
    • HC-7366
  • Patients & Caregivers
  • News & Publications
  • Contact

Publication Type: Abstract

A novel, phase 2 study in second line +, metastatic triple negative breast cancer patients shows promising clinical benefit for the combination of the immune checkpoint inhibitor, pembrolizumab (pembro), with the novel innate immune activator, Imprime PGG

HiberCell
  • About
    • Mission
    • Team
    • Careers
  • Our Science
  • Programs
    • Pipeline
    • Odetiglucan
    • HC-5404
    • HC-7366
  • News & Publications
  • Contact
Linked In

© 2023 Hibercell Inc |
Privacy Policy |
Terms & Conditions |
Expanded Access